Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 4:07 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 100 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Surgical Hemostasis Clear all

Conditions: Hemostasis
Interventions: Human thrombin, Bovine thrombin; Biological
Lead sponsor: Instituto Grifols, S.A.; Industry
Eligibility: Not listed
Enrollment: 181 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 20
States / cities: Tucson, Arizona • Los Angeles, California • Pasadena, California + 17 more

Conditions: Pediatric Surgical Procedures, Adult Surgical Procedures, Adult Gynecological Procedures, Adult Urological Procedures, Adult Thoracic Procedures
Interventions: HARMONIC 700 Shears; Device
Lead sponsor: Ethicon Endo-Surgery; Industry
Eligibility: Up to 110 Years
Enrollment: 173 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 2
States / cities: Indianapolis, Indiana • New York, New York

Conditions: Peripheral Vascular Disease, Hemorrhage
Interventions: EVICEL ™ Fibrin Sealant (Human); Biological
Lead sponsor: Ethicon, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 2
States / cities: Jacksonville, Florida

Conditions: Postoperative Pain
Interventions: RADA16 hydrogel; Device
Lead sponsor: Rutgers, The State University of New Jersey; Other
Eligibility: 18 Years and older
Enrollment: 134 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 2
States / cities: Livingston, New Jersey • Newark, New Jersey

Conditions: Benign Renal Tumors, Malignant Renal Tumors
Interventions: Laser Tissue Welding Device; Device
Lead sponsor: Laser Tissue Welding, Inc.; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Coagulation Disorder
Interventions: TAK-330, SOC 4F-PCC; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Enrollment: 440 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 13
States / cities: Arkansas City, Arkansas • Sacramento, California • Englewood, Colorado + 10 more

Conditions: Hemostasis
Interventions: Fibrinogen Concentrate (FC), Cryoprecipitate; Drug
Lead sponsor: Emory University; Other
Eligibility: 1 Day to 30 Days
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Breast Carcinoma, Colon Carcinoma, Invasive Carcinoma, Kidney Carcinoma, Liver Carcinoma, Malignant Solid Neoplasm, Multiple Myeloma, Prostate Carcinoma
Interventions: Biospecimen Collection, Laboratory Biomarker Analysis; Procedure · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 2,400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2026
U.S. locations: 1
States / cities: Rockville, Maryland

Conditions: Blood Coagulation, Disorders, Surgical Procedures, Minimally Invasive
Interventions: Fresh Frozen Plasma Transfusion; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 1 Year and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Hemophilia A
Interventions: ReFacto AF; Biological
Lead sponsor: Wyeth is now a wholly owned subsidiary of Pfizer; Industry
Eligibility: 12 Years and older · Male only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 8
States / cities: La Jolla, California • Detroit, Michigan • Chapel Hill, North Carolina + 4 more

Conditions: Cardiothoracic Surgery
Interventions: HEMOBLAST Bellows, FLOSEAL; Device
Lead sponsor: Biom'Up France SAS; Industry
Eligibility: Not listed
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 4
States / cities: Los Angeles, California • Honolulu, Hawaii • New Orleans, Louisiana + 1 more

Conditions: Surgical Bleeding
Interventions: HEMOBLAST™ Bellows, absorbable gelatin sponge with thrombin; Device
Lead sponsor: Dilon Technologies Inc.; Industry
Eligibility: 22 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 5
States / cities: Los Angeles, California • Carmel, Indiana • Baltimore, Maryland + 2 more

Conditions: Fracture Fixation, Intra-Articular Fractures, Acetabulum
Interventions: Vitagel, Standard of care; Device · Procedure
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 18 Years to 65 Years
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Cancer, Hematologic Malignancies, Multiple Myeloma, Oncology, Bone Metastases, Multiple Myeloma Bone Lesions
Interventions: Denosumab, Zoledronic acid, Placebo to Denosumab, Placebo to zoledronic acid, Denosumab (for the open-label treatment phase); Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years and older
Enrollment: 1,718 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2019
U.S. locations: 79
States / cities: Tucson, Arizona • Fayetteville, Arkansas • Anaheim, California + 67 more

Conditions: Congenital Heart Disease
Interventions: Fibrinogen Concentrate, Cryoprecipitate; Biological
Lead sponsor: Stanford University; Other
Eligibility: 1 Day to 12 Months
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 2
States / cities: Stanford, California • Emory, Georgia

Conditions: Hemostasis, Hemostatic Techniques
Interventions: ETHIZIA, SURGICEL Original; Device
Lead sponsor: Ethicon, Inc.; Industry
Eligibility: 22 Years and older
Enrollment: 108 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 6
States / cities: Los Angeles, California • St Louis, Missouri • Pennington, New Jersey + 3 more

Conditions: Postoperative Wound Haemorrhage
Interventions: Tranexamic acid, normal saline; Drug
Lead sponsor: University of Missouri-Columbia; Other
Eligibility: 18 Years and older
Enrollment: 124 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Columbia, Missouri

Conditions: Blood Loss, Surgical
Interventions: Quantra System; Diagnostic Test
Lead sponsor: HemoSonics LLC; Industry
Eligibility: 18 Years and older
Enrollment: 302 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 4
States / cities: Baltimore, Maryland • Durham, North Carolina • Charleston, South Carolina + 1 more

Conditions: Intraoperative Complications, Intraoperative Bleeding, Intraoperative Blood Loss, Hemostasis, Blood Transfusion, Postoperative Hemorrhage, Postoperative Complications, Spine Fusion, Thoracolumbar Spine
Interventions: Ostene; Device
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years to 88 Years
Enrollment: 173 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Parenchymous Tissue Surgical Bleeding
Interventions: Fibrin Sealant Grifols, Surgicel®; Biological · Device
Lead sponsor: Instituto Grifols, S.A.; Industry
Eligibility: Not listed
Enrollment: 325 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 26
States / cities: Loma Linda, California • Los Angeles, California • New Haven, Connecticut + 21 more

Conditions: Coagulation Disorder, Bleeding
Interventions: Coagulation Laboratory Testing; Diagnostic Test
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Controlling Mild to Moderate Bleeding During Surgery
Interventions: EVARREST® Fibrin Sealant Patch; Biological
Lead sponsor: Ethicon, Inc.; Industry
Eligibility: 28 Days to 17 Years
Enrollment: 35 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2025
U.S. locations: 2
States / cities: Birmingham, Alabama • New York, New York

Conditions: Intraoperative Bleeding
Interventions: BioFoam Surgical Matrix, Gelfoam Plus; Device
Lead sponsor: CryoLife, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 2
States / cities: Palo Alto, California • Seattle, Washington

Conditions: Hemostasis
Interventions: HEMOBLAST Bellows, Absorbable gelatin sponge, USP with thrombin; Device
Lead sponsor: Biom'Up France SAS; Industry
Eligibility: 21 Years and older
Enrollment: 258 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 17
States / cities: Phoenix, Arizona • Los Angeles, California • Pasadena, California + 12 more

Search by objective public record fields.

Safety and Efficacy of Topical Thrombin (Human) Grifols as an Adjunct to Hemostasis During Surgery

A Study of HARMONIC 700 Shears With Advanced Hemostasis in Pediatric and Adult Surgical Procedures

The Evicel Post-Authorization Surveillance Study

RADA16 for Adult Tonsillectomy

First-in-Human Safety Study Of Laser Tissue Welding For Surtureless Laparoscopic Partial Nephrectomy

A Study of TAK-330 to Reverse the Effects of Factor Xa Inhibitors For Adults Needing Urgent Surgery

In Vivo Effects of Fibrinogen Concentrate (FC) Versus Cryoprecipitate on the Neonatal Fibrin Network Structure After Cardiopulmonary Bypass (CPB)

Biospecimen Collection in Identifying Genetic Changes in Patients With Breast, Prostate, Colorectal, Liver, or Kidney Cancer or Multiple Myeloma Undergoing Surgery

Is Plasma Transfusion Beneficial Prior to Low-Risk Procedures in Hospitalized Patients With Blood Clotting Abnormalities?

Study Evaluating B-Domain Deleted Recombinant Factor VIII (BDDrFVIII, ReFacto AF) in Patients With Hemophilia A Undergoing Elective Major Surgery

Clinical Study Evaluating the Performance of HEMOBLAST Bellows Compared to FLOSEAL Hemostatic Matrix in Cardiothoracic Operations

Evaluation of Safety of HEMOBLAST Bellows in Spine Surgery

Hemostasis in Kocher-Langenbeck Approaches for Acetabular Surgery Using a Topical Surgical Hemostat (Vitagel)

Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Patients With Multiple Myeloma

Fibrinogen Concentrate vs Cryoprecipitate

A Study of ETHIZIA Versus SURGICEL Original in Controlling Soft Tissue Bleeding During Open Surgery

Topical Tranexamic Acid Use on Granulating Wounds Following Mohs Micrographic Surgery

Evaluation of the Clinical Performance of the Quantra System With the Quantra Surgical Cartridge

Ostene in Thoracolumbar Decompression and Fusion Evaluated With VIBE

Safety and Efficacy of Fibrin Sealant Grifols (FS Grifols) During Parenchymous Tissue Open Surgeries

Coagulation Test Changes Associated With Acute Normovolemic Hemodilution in Cardiac Surgery

The EVARREST® Pediatric Mild or Moderate Liver and Soft Tissue Bleeding Study

Adjunctive Application of BioFoam Surgical Matrix in Liver Surgery

HEMOBLAST Pivotal Clinical Investigation